At the conclusion of the inspection, the FDA issued a Form 483, outlining eight observations across the facility's units. The ...

The acquisition of Biocon's insulin brands, valued around Rs 200 crore, will add to Eris' existing insulin portfolio of Rs 50 crore, Vaidyanathan added. This acquisition also provides immediate ...

Insulin Biosimilar MarketThe global insulin biosimilar market is on track for significant expansion, with an estimated valuation of approximately USD 3,008.0 million in 2024. Exhibiting a year-on-year ...

enhancing insulin secretion and suppressing glucagon production. The hormones also slow gastric emptying and reduce food intake, which helps maximise nutrient absorption while controlling weight.

Biocon Biologics announced on Saturday, September 28, that the US Food and Drug Administration (US FDA) has completed a Current Good Manufacturing Practice (cGMP) inspection of its Insulins ...

Notable short-acting insulin companies such as Eli Lilly and Company, Novo Nordisk A/S, Sanofi, Biocon, Torrent Pharmaceuticals Ltd., Gland Pharma, Lupin, Sensile, Zydus Cadila, Cipla, Glenmark ...

Mylan President Rajiv Malik commented, "We are pleased with CHMP's decision to recommend approval of Mylan and Biocon's biosimilar insulin glargine. With approximately 60 million people living ...

Biocon Biologics is focused on improving cash flows and increasing market shares of its biosimilar products, particularly in the US and Europe. The company is dealing with rising pricing pressure ...

The Rapid Acting Insulin market is dominated by several leading companies, including Adocia, Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind ...

Biocon’s biosimilar foray began with a partnership with U.S.-based Mylan (now Viatris) for biosimilar monoclonal antibodies ...